Evidence map›Paper›PMID 36387192›Full record

ArticleFrontiers in oncology2022

Relevance of the TRIAP1/p53 axis in colon cancer cell proliferation and adaptation to glutamine deprivation.

Kenza Nedara, Camille Reinhardt, Emilie Lebraud, Giuseppe Arena, Céline Gracia, Valérie Buard, Catherine Pioche-Durieu, Florence Castelli, Benoit Colsch, Paule Bénit and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. The crisscross between p53 and metabolism in cancer.Acta biochimica et biophysica Sinica · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Kenza NedaraUniversité Paris-Saclay, CNRS, Gustave Roussy, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Villejuif, France.
Camille ReinhardtUniversité Paris-Saclay, CNRS, Gustave Roussy, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Villejuif, France.
Emilie LebraudInstitut de Radioprotection et de Sûreté Nucléaire Laboratoire de radiobiologie des Expositions Médicales (IRSN), Fontenay-aux-Roses, France.
Giuseppe ArenaUniversité Paris-Saclay, INSERM U1030, Gustave Roussy, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France.
Céline GraciaUniversité Paris-Saclay, CNRS, Gustave Roussy, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Villejuif, France.
Valérie BuardInstitut de Radioprotection et de Sûreté Nucléaire Laboratoire de radiobiologie des Expositions Médicales (IRSN), Fontenay-aux-Roses, France.
Catherine Pioche-DurieuUniversité Paris Cité, CNRS, Institut Jacques Monod, Paris, France.
Florence CastelliUniversité Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (MTS), MetaboHUB, Gif sur Yvette, France.
Benoit ColschUniversité Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (MTS), MetaboHUB, Gif sur Yvette, France.
Paule BénitUniversité Paris Cité, INSERM U1141, NeuroDiderot, Paris, France.
Pierre RustinUniversité Paris Cité, INSERM U1141, NeuroDiderot, Paris, France.
Benoit AlbaudInstitut Curie, PSL University, ICGex Next-Generation Sequencing Platform, Paris, France.
Pierre GestraudInstitut Curie, Centre for Computational Biology (CBIO), INSERM U900, Mines ParisTech, Paris, France.
Sylvain BaulandeInstitut Curie, PSL University, ICGex Next-Generation Sequencing Platform, Paris, France.
Nicolas ServantInstitut Curie, Centre for Computational Biology (CBIO), INSERM U900, Mines ParisTech, Paris, France.
Eric DeutschUniversité Paris-Saclay, INSERM U1030, Gustave Roussy, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France.
Jean-Marc VerbavatzUniversité Paris Cité, CNRS, Institut Jacques Monod, Paris, France.
Catherine BrennerUniversité Paris-Saclay, CNRS, Gustave Roussy, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Villejuif, France.
Fabien MilliatInstitut de Radioprotection et de Sûreté Nucléaire Laboratoire de radiobiologie des Expositions Médicales (IRSN), Fontenay-aux-Roses, France.
Nazanine ModjtahediUniversité Paris-Saclay, CNRS, Gustave Roussy, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Villejuif, France.
Université Paris-Saclay · FRInstitut Curie · FRInstitut de Radioprotection et de Sûreté Nucléaire · FRInserm · FRInstitut Gustave Roussy · FRCentre National de la Recherche Scientifique · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRHôpital Robert-Debré · FRInstitut de Biologie et Technologies · FRInstitut Jacques Monod · FRNeuroDiderot

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human TRIAP1 (TP53-regulated inhibitor of apoptosis 1; also known as p53CSV for p53-inducible cell survival factor) is the homolog of yeast Mdm35, a well-known chaperone that interacts with the Ups/PRELI family proteins and participates in the intramitochondrial transfer of lipids for the synthesis of cardiolipin (CL) and phosphatidylethanolamine. Although recent reports indicate that TRIAP1 is a prosurvival factor abnormally overexpressed in various types of cancer, knowledge about its molecular and metabolic function in human cells is still elusive. It is therefore critical to understand the metabolic and proliferative advantages that TRIAP1 expression provides to cancer cells. Here, in a colorectal cancer cell model, we report that the expression of TRIAP1 supports cancer cell proliferation and tumorigenesis. Depletion of TRIAP1 perturbed the mitochondrial ultrastructure, without a major impact on CL levels and mitochondrial activity. TRIAP1 depletion caused extramitochondrial perturbations resulting in changes in the endoplasmic reticulum-dependent lipid homeostasis and induction of a p53-mediated stress response. Furthermore, we observed that TRIAP1 depletion conferred a robust p53-mediated resistance to the metabolic stress caused by glutamine deprivation. These findings highlight the importance of TRIAP1 in tumorigenesis and indicate that the loss of TRIAP1 has extramitochondrial consequences that could impact on the metabolic plasticity of cancer cells and their response to conditions of nutrient deprivation.

Indexed as

coiled-coil-helix-coiled-coil-helix domain (CHCHD)-containing proteinscolon cancerglutamine starvationlipid homeostasismitochondriap53-mediated stress responseTRIAP1/Mdm35

Identifiers

PMID36387192
PMCPMC9661196
OpenAlexW4307870641

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.